MNKD MannKind Corp
Company Analysis
Latest News
🔴 MannKind is trading 5.5% down today after wider Q2 GAAP loss
MannKind is trading 5.5% down at $3.88 as investors continue weighing its August 5 earnings report and wider GAAP loss. - Second-quarter revenue rose 43% to...
🔴 MannKind is trading 6% down in pre-market after post-earnings caution over launch spending
MannKind is trading 6.07% down now at $3.86 after investors continued reassessing its August 5 earnings report. - Second-quarter revenue rose 43% year over...
🟢 MannKind is trading 5% up today after Q2 revenue rose 43%
MannKind is trading 5% up at $4.08 after recovering from the August 6 selloff following its second-quarter results, as revenue reached $109.4 million, up 43%...
🔴 MannKind is trading 6.3% down today after higher launch spending
MannKind is trading at $3.79 (-6.34%) after investors focused on higher launch spending and a wider GAAP loss following the August 5 earnings release. •...
🔴 MannKind is trading 5.9% down today after Q2 earnings miss and higher operating expenses
MannKind is trading at $3.86 (5.9% down) in pre-market after its second-quarter 2026 report showed a net loss of $0.06 per share, missing analyst expectations...
MannKind's second quarter revenue of $109.4M beat estimates while EPS missed on higher spending.
MannKind Corporation reported second quarter 2026 revenues of $109.4 million, a 43% increase year-over-year, driven by the inclusion of Furoscix sales and...
🟢 MannKind is trading 5% up today ahead of Q2 earnings and biotech rally
MannKind is trading 5% up today at $3.99 as investors position ahead of its August 5, 2026, second-quarter earnings report. • Traders are betting on solid...
🟢 MannKind is trading 5% up today ahead of Q2 earnings
MannKind is trading at $3.99 (5% up) in pre-market, rebounding from recent weakness as traders position ahead of the August 5, 2026, Q2 earnings report. •...
MannKind Corp Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect MannKind to report Q2 2026 revenue of $108.8 million and a loss of $0.02 per share, while the stock currently trades around $3.95 compared to a...
🔴 MannKind is trading 5.2% down today tracking a broader biotech selloff
MannKind is trading 5.2% down today at $3.90, tracking a sharp pullback in the broader biotechnology sector. • The decline appears driven by risk-off...
🟢 MannKind is trading 5.9% up today amid a broad market rally
MannKind is trading 5.9% up today at $4.04 amid a broad market rally in U.S. equities. • The move appears aligned with a strong risk-on tone lifting many...
MannKind Announces $50M Private Placement Following FDA Approval of Furoscix ReadyFlow™
MannKind Corporation announced it has raised approximately $50.0 million in gross proceeds through a private placement with institutional investors. The...
🟢 MannKind surges 6% today on FDA approval of Furoscix ReadyFlow™ and $50M private placement
MannKind is trading about 6% up today at $4.11 following two significant announcements: • The U.S. Food and Drug Administration (FDA) approved Furoscix...
🟢 MannKind is trading 6.2% up today after announcing a $50 million private placement
MannKind is trading 6.2% higher at $4.13 in pre-market sessions, following an announcement of a private placement to certain institutional investors. The...
🟢 MannKind is trading 5% up today amid a broader biotech sector rally
MannKind is trading at $4.18 (+5.03%) as the stock climbs alongside a broader risk-on tone in the biotechnology sector, despite a lack of company-specific...